Index of /pdfs

      Name                    Last modified       Size  Description


[DIR] Parent Directory        19-May-2004 11:02      -  
[   ] SchedulingOrder.pdf     16-Jun-2004 11:50   372k  
[   ] CourtRuling2.pdf        04-May-2004 14:19   3.3M  
[   ] CourtRuling.pdf         04-May-2004 13:44    30k  
[   ] Phar10K.pdf             15-Apr-2004 10:25   477k  
[   ] PharmaNeticsPostHear..> 14-Apr-2004 13:49   1.5M  
[   ] AventisPostHearingBr..> 14-Apr-2004 13:48   1.6M  
[   ] FinalComplaint-v1.PDF   04-Nov-2003 08:46   1.9M  
[   ] Royston.pdf             24-Jul-2003 15:36    84k  
[   ] Diez.pdf                24-Jul-2003 14:58   1.4M  
[DIR] pi_languages/           17-Jul-2003 17:30      -  
[   ] Enoxcase1CCU_012003.pdf 06-May-2003 11:13   244k  
[   ] Hermiller.pdf           06-May-2003 10:54   1.5M  
[   ] Cho-ECT-AJC.pdf         06-May-2003 10:29   1.1M  
[   ] 383.pdf                 06-May-2003 10:20   1.1M  
[   ] FINAL02AR.pdf           01-May-2003 09:20   2.9M  
[DIR] pi/                     27-Mar-2003 08:56      -  
[DIR] packageinserts/         27-Mar-2003 08:55      -  
[DIR] inserts/                22-Jan-2003 08:54      -  
[   ] ect_datasheet.pdf       14-Aug-2002 10:38    15k  
[   ] ect_instructionsheet..> 14-Aug-2002 10:38    10k  
[   ] 1900013.06.pdf          24-Jun-2002 14:33   154k  
[   ] pharm.pdf               19-Apr-2002 09:30   1.4M  
[   <!-- bb --><!-- /bb --><div style='float:left;'></div><div style='float:left;'></div><font size=This press release contains forward-looking statements regarding future events and the future performance of PharmaNetics that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include risks related to market acceptance, clinical trials and dependence on third party distributors and collaborative partners, including, in particular with regard to the legal proceedings commenced against its development partner, Aventis Pharmaceuticals, which action includes without limitation the following specific risks: material monetary costs associated with the litigation, even if successful; uncertainty of obtaining a favorable outcome; the potentially significant harm to PharmaNetics’ business and financial condition and prospects if it is not successful in timely prosecuting the litigation; jeopardizing strategic relationships with other existing or potential collaborative partners; harmful delays in meeting sales objectives, even if the litigation is successful; and disruption of management time and resources to pursue the litigation.  Information concerning these and other of the factors that could cause results to differ materially from those in the forward-looking statements is contained in the Company’s filings with the Securities and Exchange Commission, including Form 10-K, Form 10-Q and Form 8-K reports.